Deprozel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deprozel

Deprozel is a synthetic psychotropic agent and a prescription medicine utilized to modulate neurochemical balance within the central nervous system. Its primary purpose is to provide pharmacological support for managing mood and emotional stability, which is clinically recognized for conditions associated with disruptions in serotonin signaling. The drug is consistently provided as a single-ingredient product, focusing the therapeutic effect entirely on the unique properties of its active component.

What Type of Medicine is Deprozel?

Deprozel belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class, making it an established type of antidepressant. The active ingredient is Paroxetine, typically present as its hydrochloride or mesylate salt. Pharmacological data indicates that Paroxetine is characterized as a potent inhibitor of serotonin reuptake among available SSRIs. As a chemically synthesized phenylpiperidine derivative, it represents a targeted approach in pharmacotherapy, selectively influencing the serotonin system while demonstrating minimal clinically relevant activity toward other receptors.

Deprozel's Composition and General Purpose

The medication is available for oral administration, predominantly in the form of a film-coated tablet or, for patients requiring flexible dosing, an oral suspension, both designed for systemic absorption. The core mechanism involves selectively inhibiting the reabsorption, or reuptake, of the neurotransmitter serotonin by nerve cells, thereby increasing serotonin's availability in the synaptic space. This enhancement of serotonergic activity is the essential function by which Deprozel helps achieve the stabilization of emotional balance and the regulation of affective states, representing its general therapeutic contribution.

Regulatory References

  1. Selective Serotonin Reuptake Inhibitors
  2. antidepressants
  3. NIH Classification

What side effects are possible with Deprozel?

Possible Side Effects and Safety Information

The safety profile of Deprozel (Paroxetine) is documented through formal regulatory classifications, detailing possible adverse reactions and specific safety constraints defined by government health authorities.

Adverse reactions are classified by the frequency of their occurrence, using regulatory standards (e.g., Very Common, Common, Rare). Very Common (ge 10%) adverse events listed in official labeling include nausea and various forms of sexual dysfunction, such as abnormal ejaculation, impotence, and decreased libido. Common (1% to 10%) reactions affecting the Nervous System and Gastrointestinal systems include headache, somnolence, dizziness, tremor, dry mouth, constipation, diarrhea, and insomnia. Reactions are formally grouped by the body system affected, a practice standard in regulatory documents.

The official labeling includes specific warnings regarding serious adverse reactions. A key regulatory alert involves the increased risk of Suicidal Thoughts and Behaviors, particularly in young adults and pediatric patients (a population for which the drug is generally not approved). Other serious, though rare, documented risks include Serotonin Syndrome, Seizures, and Angle-Closure Glaucoma.

Specific safety considerations apply to certain patient groups. A reduced initial dosage is required for older adults and individuals with severe hepatic or renal impairment due to documented increases in blood plasma levels. Furthermore, regulatory documents specify that potential risks exist for the fetus when the medicine is used during pregnancy. Close monitoring is explicitly advised during the initial few months of therapy or following dose adjustments, and a discontinuation syndrome is noted upon stopping the medicine, requiring gradual tapering.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose involving Deprozel requires immediate medical attention. This emergency action is mandated in regulatory documents due to the potential for severe, life-threatening outcomes.

Documented Overdose Manifestations

Regulatory documentation describes several clinical signs associated with Paroxetine overdose. These commonly include central nervous system and autonomic effects such as somnolence (drowsiness), tremor, diaphoresis (sweating), and gastrointestinal issues like nausea and vomiting. Cardiovascular changes, particularly tachycardia (rapid heartbeat), may also be observed. More significant manifestations, which typically occur with higher exposure or when the drug is combined with other substances, can progress to seizures and severe central nervous system depression leading to coma.

Severe Outcomes and Management

The most serious outcome reported in official labeling is the development of Serotonin Syndrome, a potentially life-threatening condition. If symptoms of this syndrome are suspected, the drug must be immediately discontinued, and urgent medical care must be sought for supportive treatment. Management of a Paroxetine overdose is entirely symptomatic and supportive as no specific antidote is known. Close monitoring of vital signs and continuous observation for potential complications are officially required. Furthermore, increased plasma concentrations of the active ingredient are documented in patients with severe hepatic or renal impairment, which is a consideration related to potential overdose severity.

Therapeutic Uses of Deprozel

What Deprozel treats: Main Uses and Benefits

The therapeutic application of Deprozel (Paroxetine) is used across domains where additional symptomatic support is needed, targeting symptoms that interfere with daily functioning and contribute to emotional or physiological stress. This medication is commonly used to help with multiple symptomatic domains, including Major Depressive Disorder (MDD), Panic Disorder, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Social Anxiety Disorder, Posttraumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD). It is also applied in addressing moderate-to-severe hot flashes associated with menopause.

The medication may assist with managing symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes. This application supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

“This application supports the patient during difficult episodes by easing distress.”

Quick Fact: Addressing Episodic Disruption

Deprozel is commonly used in clinical scenarios where symptoms escalate temporarily, providing supportive relief when manifestations interfere with routine activities and functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Deprozel (Paroxetine) eligibility is determined by strict regulatory criteria concerning co-medication, age, and patient health status. Use is established and approved for adults 18 years and older.

Contraindicated Populations

Official labeling mandates that Deprozel must not be used by patients with a known hypersensitivity to the drug or those concurrently taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI. It is also contraindicated for patients taking Pimozide or Thioridazine.

Restricted and Non-Recommended Use

Population/Condition Eligibility Status (Regulatory Basis)
Children and Adolescents (Under 18) Not Approved (FDA) or Not Recommended (EMA) due to safety concerns regarding suicidality risk.
Older Adults (Geriatric Use) Use is Restricted; a reduced initial dosage is required due to increased plasma concentrations [Source: FDA Label].
Severe Hepatic or Renal Impairment Use is Restricted; a reduced initial dosage is required due to altered drug clearance [Source: FDA Label].
Pregnancy Use is conditional; exposure is associated with increased risk of cardiovascular malformations (First Trimester) and PPHN (Late Pregnancy).

Use also requires caution and screening in patients with a history of seizure disorders or undiagnosed Bipolar Disorder.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory labeling specifies several important drug interactions, categorized by mechanism and clinical consequence.


Interaction Classification Specific Interacting Medicines/Categories
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs) (including Linezolid and intravenous Methylene Blue), Pimozide, Thioridazine
Use with Caution/Monitoring CYP2D6 Substrates, Serotonergic Drugs, Drugs Affecting Hemostasis (e.g., Warfarin, Aspirin, NSAIDs)

Deprozel is contraindicated with MAOIs due to the risk of Serotonin Syndrome; a 14-day washout period is required after stopping an MAOI before starting Deprozel, and a 5-week washout period is required after stopping Deprozel before starting an MAOI. The combination with Pimozide and Thioridazine is also contraindicated due to the potential for QT interval prolongation and increased plasma concentrations of these drugs.

As a potent inhibitor of the CYP2D6 enzyme system, Deprozel can significantly increase the exposure of co-administered medicines metabolized by this pathway, such as certain antipsychotics, antiarrhythmics, and tricyclic antidepressants. Concurrent use with other serotonergic drugs (e.g., Triptans, Tryptophan, Tramadol) requires caution due to the potential for Serotonin Syndrome. Additionally, combination with drugs that interfere with hemostasis, including anticoagulants like Warfarin, requires careful monitoring due to an increased risk of bleeding.

Mechanism of Action

Targeting the Serotonin Transporter for Neurochemical Enhancement

Deprozel's mechanism is defined by the selective inhibition of the Serotonin Transporter (SERT) protein, the primary structure responsible for recycling the neurotransmitter serotonin (5-HT) from the synapse. By blocking this reuptake mechanism, the active component immediately increases the concentration and duration of serotonin availability in the synaptic cleft. This foundational molecular action is essential for promoting initial, enhanced signaling across the serotonergic system, which defines the drug's resultant physiological activity.


Time-Dependent Adaptation and Affective Modulation

The basis for the sustained physiological effect is a subsequent, slower process of neuroadaptation. The long-term presence of elevated serotonin triggers the desensitization and downregulation of presynaptic feedback receptors (autoreceptors), effectively removing a 'brake' on 5-HT release. This secondary, time-dependent change establishes a new, stable, and elevated level of serotonergic activity, which serves to modulate the activity within the brain's complex affective and limbic circuits, contributing to an altered baseline of serotonergic activity.

Dosage and Administration Information

Deprozel (Paroxetine) is administered exclusively by the oral route as a once-daily dose, typically taken in the morning. Administration may be done with or without food, though the oral suspension formulation requires vigorous shaking prior to use. The medication is available as immediate-release (IR) tablets, extended-release (CR) tablets, and an oral suspension.

Standard adult dosing for immediate-release tablets often begins at 20 mg daily, though a lower starting dose of 10 mg is utilized for certain conditions, such as Panic Disorder. When the clinical response is inadequate, the dose may be increased in increments of 10 mg per day at intervals of at least one week, up to a maximum of 60 mg daily for specific uses. Extended-release tablets are titrated in 12.5 mg increments.

Specific populations require mandatory dosage adjustments: Older adults and patients with severe hepatic or renal impairment must initiate treatment at a lower dose (10 mg IR or 12.5 mg CR) and should not exceed a reduced maximum daily limit (e.g., 40 mg IR). The treatment course is typically for a sustained duration (e.g., at least six months). A key administration constraint is that extended-release tablets must be swallowed whole and must not be crushed, chewed, or cut to maintain the intended release profile. Upon cessation, the dosage must be reduced gradually according to a tapering schedule to complete the course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early and Phase 2 Research

Preliminary and Phase 2 studies focused on the agent's potential mechanism of action and dose optimization. Studies investigated the agent's mechanism of action and explored the resulting effects on inflammation. These studies informed the design and execution of later-stage trials.

Studies have also explored whether the agent influenced pain and discomfort, particularly in individuals with inflammatory conditions.


Phase 3 Clinical Trials

Large-scale Phase 3 studies investigated whether the quality of life and effects on symptoms were observed in patients receiving the agent compared to those receiving placebo or an active comparator.

  • Core Study 1 (Adult Patients): Phase 3 trials reported on the agent's effects for adult patients. Research evaluated whether effects were observed within the first week of treatment.
  • Core Study 2 (Long-term Outcomes): Studies have explored whether the frequency and severity of flare-ups were influenced by the agent, and research has examined long-term outcomes. Studies also reported that a common reason for discontinuation among participants was lack of perceived benefit.

Safety and Tolerability Profiles

Clinical trial data provides information on the adverse events reported across various patient populations.

  • Reported common side effects include injection-site reactions, headache, and upper respiratory tract infections.
  • More serious, but rare, adverse events have included opportunistic infections and allergic reactions.
  • Studies have compared the agent to older treatment options to gather comparative safety data.

Use in Specific Populations

Research has explored the agent's potential role in various subsets of patients, including those with different disease severity levels and those who have not responded to previous treatments.

  • Mild-to-Moderate Disease: Research has examined the agent as a potential option in individuals with mild-to-moderate disease.
  • Pediatric Use: Research indicates that evidence remains limited regarding the use of this agent in pediatric populations. Studies are ongoing to evaluate its potential effects and reported adverse events in children and adolescents.

Frequently Asked Questions (FAQ)

Common questions about Deprozel (FAQ)


Q: What is the main reason doctors prescribe Deprozel?

A: According to official regulatory documents, Deprozel (Paroxetine) is indicated in adults for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), and Posttraumatic Stress Disorder (PTSD). Specific formulations may also be indicated for Premenstrual Dysphoric Disorder (PMDD). This information aligns with the drug’s general purpose, which is to support the stabilization of emotional balance and mood.


Q: What happens if I miss a day of taking Deprozel?

A: Official patient information generally advises that if the dose is remembered before bedtime on the same day, it is generally recommended that the dose be taken immediately. However, if the dose is not remembered until the next day, official patient information generally advises skipping the missed dose and returning to the regular schedule if the next dose time is near. Taking two doses together is generally advised against.


Q: Is Deprozel considered a controlled substance?

A: No, official regulatory classification documents indicate that Deprozel (Paroxetine) is not a federally controlled substance. Although it is a prescription psychotropic agent, it is not placed in the scheduling categories used to classify controlled drugs.


Q: Does taking Deprozel affect my ability to drive or operate machinery?

A: Official product information cautions that common side effects, such as dizziness and somnolence (sleepiness), may affect a person’s concentration or motor skills. Patients are generally advised to use caution regarding driving or operating complex machinery until the effects of the medication on individual alertness are known.


Q: Does Deprozel interact with herbal supplements?

A: The potent herbal supplement St. John’s wort is specifically known to interact with Deprozel and should not be used together due to an increased risk of severe side effects. Regulatory sources emphasize the importance of disclosing all concurrent products to a healthcare provider, as other herbal remedies and supplements have limited safety data when combined with Deprozel.


Q: Does Deprozel typically cause weight gain or loss?

A: Regulatory adverse reaction reports indicate that changes in weight are documented side effects of Deprozel. Official clinical trial data shows that both weight gain and weight loss have been reported in patients taking the medicine. The extent of this change can vary among individuals.


Q: Is there a generic version of Deprozel available?

A: Yes, the active ingredient in Deprozel is paroxetine, and this compound is available as a generic medicine. Generic versions of paroxetine are available in various formulations, as confirmed by regulatory product listings.


Q: What should I do if I notice an unusual skin reaction after starting Deprozel?

A: Official patient information notes that severe allergic or serious skin reactions require prompt medical attention should signs occur. These rare but serious reactions may include the development of hives, difficulty breathing, swelling of the face, or a skin rash accompanied by blistering and peeling.


Q: How long does Deprozel typically stay in my system?

A: According to the official pharmacokinetic data, the mean elimination half-life of paroxetine is approximately 21 hours in adults. The half-life is the time it takes for half of the drug to be eliminated, meaning it takes several days for the drug to be almost fully cleared from the body.


Q: Does Deprozel affect blood pressure?

A: Official adverse reaction reports document that the drug can have some effects on the cardiovascular system. Adverse events have included reports of both hypertension (high blood pressure) and hypotension (low blood pressure) in some patients taking the medicine.


Q: Is there a risk of dependency or addiction with Deprozel?

A: Deprozel is not classified as a controlled substance and has not been linked to abuse or psychological dependence. However, discontinuation syndrome is noted when the medicine is stopped, and this typically necessitates the use of a gradual tapering protocol.


Q: Do alcohol and Deprozel interact?

A: Regulatory and patient counseling information generally advises that individuals should avoid or limit the consumption of alcohol while using Deprozel. Alcohol may amplify certain central nervous system effects of the medicine, which could potentially lead to increased drowsiness or more impaired judgment.


Q: Can Deprozel cause mood swings?

A: Official warnings and precautions state that, like other antidepressant medications, Deprozel may potentially activate mania or hypomania (mood elevation) in some patients. Patients, especially those with undiagnosed bipolar disorder, should be monitored for new or worsening symptoms and significant changes in behavior or mood.


Q: Are there any specific laboratory tests required before starting Deprozel?

A: Before starting treatment, official guidelines advise that healthcare professionals screen patients for a personal or family history of bipolar disorder or mania. While this may not always involve a physical lab test, this comprehensive pre-treatment assessment is specified in guidelines for determining eligibility.


Q: Can Deprozel affect blood sugar levels?

A: The regulatory label does not typically cite blood sugar changes as a common or serious side effect. However, one study noted an increased effect on blood glucose when paroxetine was used in combination with another specific medicine (pravastatin).


Q: What if I'm already taking vitamins, can I still take Deprozel?

A: While regulatory labeling does not detail specific interactions with every common vitamin, general caution is advised. Patient counseling information stresses the importance of informing a health professional about all current products being taken, including any vitamins or supplements.


Q: What is the purpose of the black box warning on Deprozel?

A: Deprozel carries an official Boxed Warning—the most serious regulatory alert—to inform patients and caregivers about the increased risk of suicidal thoughts and behaviors. This risk is particularly noted in children, adolescents, and young adults (up to 24 years old) when they start the medicine or when the dose is changed.


Q: Can Deprozel make my existing medical condition worse?

A: Official warnings specify that caution is necessary for patients with a history of certain pre-existing conditions. These conditions include Seizure Disorders, Bipolar Disorder, Bleeding or Clotting disorders, Angle-Closure Glaucoma, and low sodium (Hyponatremia), as the drug may affect these conditions.


Q: Is it safe to take Deprozel during pregnancy or while breastfeeding?

A: Regulatory documents indicate that use during the first trimester of pregnancy is associated with an increased risk of certain cardiovascular malformations. For breastfeeding, the drug is generally considered a preferred choice among antidepressants due to typically low levels in breastmilk, but monitoring of the infant is generally advised.


Q: What are the signs of an allergic reaction to Deprozel?

A: Official patient counseling information lists key signs of a severe allergic reaction that are grounds for immediate medical evaluation. These signs can include difficulty breathing, noticeable swelling of the face or throat, the development of hives, or a severe skin rash that involves blistering, peeling, or painful burning eyes.


Q: Does Deprozel have a potential for causing cognitive changes?

A: Regulatory reports on adverse reactions confirm common effects on the nervous system, such as somnolence (sleepiness), dizziness, tremor, and insomnia. These documented effects are often associated with changes in cognitive function or general mental alertness.

How should Deprozel be stored and disposed of?

How to Store and Dispose of Deprozel

Official labeling for Deprozel (Paroxetine) strictly defines the required conditions for storage and disposal to maintain product stability and safety.


Storage Requirements

  • Temperature and Environment: Store the medication at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F). It must be protected from excess moisture, excess heat, and freezing.
  • Container and Protection: Keep the product in its original container and ensure the container is tightly closed. The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Deprozel should be disposed of primarily through a drug take-back program. If a take-back program is unavailable, the medicine can be discarded in the household trash only after being mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deprozel found in:

A-Z Index: